X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32) 32
female (29) 29
adult (25) 25
middle aged (25) 25
index medicus (24) 24
rheumatoid arthritis (24) 24
male (23) 23
rheumatology (22) 22
arthritis, rheumatoid - drug therapy (14) 14
antirheumatic agents - therapeutic use (12) 12
double-blind method (11) 11
methotrexate (11) 11
clinical trials (10) 10
treatment outcome (10) 10
tumor necrosis factor-tnf (10) 10
aged (9) 9
care and treatment (9) 9
disease (9) 9
inflammation (9) 9
severity of illness index (9) 9
antirheumatic agents - adverse effects (8) 8
infliximab (8) 8
patients (8) 8
arthritis (7) 7
drug dosages (7) 7
pharmacokinetics (7) 7
safety (7) 7
skin and connective tissue diseases (7) 7
1506 (6) 6
arthritis, rheumatoid - blood (6) 6
clinical and epidemiological research (6) 6
expression (6) 6
scleroderma (6) 6
young adult (6) 6
abridged index medicus (5) 5
antibodies, monoclonal - therapeutic use (5) 5
biomarkers - blood (5) 5
case-control studies (5) 5
dosage and administration (5) 5
drug therapy (5) 5
drug therapy, combination (5) 5
immunogenicity (5) 5
immunology (5) 5
original (5) 5
osteoporosis (5) 5
rheumatic diseases (5) 5
rituximab (5) 5
studies (5) 5
systemic sclerosis (5) 5
therapy (5) 5
antibodies (4) 4
antirheumatic agents - pharmacokinetics (4) 4
apoptosis (4) 4
biological products (4) 4
biosimilar pharmaceuticals - adverse effects (4) 4
biosimilar pharmaceuticals - therapeutic use (4) 4
c-reactive protein (4) 4
classification (4) 4
criteria (4) 4
dmards (4) 4
double-blind (4) 4
inadequate response (4) 4
lupus (4) 4
medicine, general & internal (4) 4
methotrexate - therapeutic use (4) 4
musculoskeletal diseases (4) 4
rheumatism (4) 4
rituximab - adverse effects (4) 4
rituximab - therapeutic use (4) 4
systemic lupus erythematosus (4) 4
time factors (4) 4
adolescent (3) 3
aneurysm (3) 3
antibodies, monoclonal - pharmacology (3) 3
antirheumatic agents - administration & dosage (3) 3
arthritis, rheumatoid - complications (3) 3
autoimmune diseases (3) 3
biomedicine (3) 3
biosimilar pharmaceuticals - pharmacokinetics (3) 3
bone density - drug effects (3) 3
cancer research (3) 3
cells (3) 3
complications (3) 3
cytokines (3) 3
interstitial lung disease (3) 3
medicine (3) 3
medicine & public health (3) 3
modifying antirheumatic drugs (3) 3
molecular medicine (3) 3
morphea (3) 3
oncology (3) 3
original research article (3) 3
pharmaceutical industry (3) 3
pharmacology & pharmacy (3) 3
pharmacotherapy (3) 3
postmenopausal women (3) 3
proteins (3) 3
pyrimidines - administration & dosage (3) 3
pyrimidines - therapeutic use (3) 3
receptor (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2013, Volume 72, Issue 10, pp. 1613 - 1620
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2013, Volume 72, Issue 10, pp. 1605 - 1612
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1679 - 1687
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 04/2016, Volume 75, Issue 4, pp. 687 - 695
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | NECROSIS-FACTOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PLUS METHOTREXATE | AMERICAN-COLLEGE | OPEN-LABEL | COMBINATION | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2016, Volume 75, Issue 6, pp. 1024 - 1033
ObjectivesTo explore the effects of tofacitinib—an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA)—with or without methotrexate... 
JAK INHIBITOR | MODIFYING ANTIRHEUMATIC DRUGS | SMALLEST DETECTABLE DIFFERENCE | INADEQUATE RESPONSE | JOINT DAMAGE | DOUBLE-BLIND | STRUCTURAL DAMAGE | PLACEBO-CONTROLLED TRIAL | RHEUMATOLOGY | PROGRESSION | CP-690,550 | Bone Marrow Diseases - etiology | Wrist Joint - diagnostic imaging | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Arthritis, Rheumatoid - complications | Synovitis - diagnostic imaging | Arthritis, Rheumatoid - diagnostic imaging | Edema - diagnostic imaging | Bone Marrow Diseases - drug therapy | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Synovitis - etiology | Adult | Female | Drug Therapy, Combination | Bone Marrow - drug effects | Synovitis - drug therapy | Piperidines - administration & dosage | Double-Blind Method | Pyrimidines - administration & dosage | Treatment Outcome | Edema - drug therapy | Hand - diagnostic imaging | Disease Progression | Edema - etiology | Magnetic Resonance Imaging | Bone Density - drug effects | Bone Marrow Diseases - diagnostic imaging | Methotrexate - administration & dosage | Care and treatment | Usage | Tofacitinib | Rheumatoid arthritis | Clinical trials | Dosage and administration | Methotrexate | Clinical and Epidemiological Research | DMARDs (synthetic) | Rheumatoid Arthritis | Inflammation | 1506
Journal Article
Reumatologia, ISSN 0034-6233, 2015, Volume 53, Issue 3, pp. 117 - 118
Journal Article